Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
We bring innovative medicines to people living with orphan and rare diseases and coagulation disorders, working hand in hand with Colombia's healthcare system.
We work with plasma-derived therapies for small but highly vulnerable populations, where timely access and continuity of treatment can change the natural course of the disease.
We base our work on data from official sources such as the Cuenta de Alto Costo (High-Cost Account), and on current Colombian healthcare regulations, promoting the appropriate and sustainable use of treatments.
We have a robust pharmacovigilance section where suspected adverse events related to our products can be reported, in accordance with international standards and local regulatory requirements.
At Hemova, we focus on diseases and clinical conditions that require highly specialized treatments. Our therapeutic areas include Rh factor incompatibility, hepatitis B, hemophilia and other coagulation disorders, as well as the use of plasma volume expanders.
We focus on preventing perinatal hemolytic disease when there is incompatibility between the mother's Rh factor and the baby's, through the use of Anti-D immunoglobulins at key moments during pregnancy and the postpartum period.
Prevention and management of hepatitis B virus (HBV) infection in exposed or high-risk individuals, combining vaccination and the use of specific immunoglobulin to reduce the likelihood of infection and its complications.
We focus on the management of hemophilia A and B and other inherited coagulopathies (including coagulation factor X deficiency), through replacement of coagulation factors and other plasma proteins.
An area focused on the use of human albumin as a plasma volume expander in selected clinical settings, where it is necessary to support circulating volume and contribute to the patient's hemodynamic stability under medical supervision.
The diseases we address are uncommon, but their impact on quality of life and the healthcare system is significant. These figures help illustrate the importance of comprehensive, timely, and safe care.
As of February 28, 2024, 6,285 people with a coagulopathy were reported in Colombia; nearly half were cases of hemophilia, and the remainder corresponded to other conditions such as von Willebrand disease and deficiencies of other factors.
As of February 28, 2025, the Cuenta de Alto Costo reported 4,215 people with hemophilia in the country, of whom 807 were women - highlighting the increasing recognition of the condition in the female population as well.
As of epidemiological week 28 of 2025, 1,571 hepatitis B cases had been reported in Colombia, with an incidence rate of 3.0 per 100,000 inhabitants, according to the Colombian National Institute of Health (Instituto Nacional de Salud).
Source: Cuenta de Alto Costo (CAC) and Instituto Nacional de Salud (INS). Figures may be updated as new reports become available.
At Hemova, we work in the responsible commercialization of plasma-derived medicines for orphan and rare diseases, coagulation disorders, and situations requiring plasma volume support.
Our work connects patients, medical teams, and healthcare institutions around a shared goal: achieving safe, timely, and sustainable treatments.
At Hemova, we understand that behind every diagnosis there are stories, families, and life projects. That is why we aim to be a trusted partner to the healthcare system - bringing together scientific knowledge and a human perspective. Staying up to date, listening to stakeholders across the system, and acting transparently are essential to how we work.
To bring highly specialized, innovative therapies to people living with orphan and rare diseases, coagulation disorders, and high clinical-impact conditions - working alongside Colombia's healthcare system to support access, appropriate use, and treatment safety.
To be a leading reference company in Latin America in the management of innovative therapies for orphan, rare, and high-cost diseases - recognized for our commitment to patients, alignment with scientific evidence, and coordinated work with healthcare institutions and professionals.
Magnis eros arcu consequat imperdiet lacus porta ac convallis, hendrerit curabitur dictumst et natoque placerat pellentesque.
Magnis eros arcu consequat imperdiet lacus porta ac convallis, hendrerit curabitur dictumst et natoque placerat pellentesque.
Magnis eros arcu consequat imperdiet lacus porta ac convallis, hendrerit curabitur dictumst et natoque placerat pellentesque.
Magnis eros arcu consequat imperdiet lacus porta ac convallis, hendrerit curabitur dictumst et natoque placerat pellentesque.
Mauris id nunc pellentesqu et consequat massa ut rutrum
Magnis eros arcu consequat imperdiet lacus porta ac convallis, hendrerit curabitur dictumst et natoque placerat pellentesque.
Magnis eros arcu consequat imperdiet lacus porta ac convallis, hendrerit curabitur dictumst et natoque placerat pellentesque.
"The transition to solar was seamless, and their team provided exceptional service from consultation to installation. We are thrilled with the savings and sustainability impact."
Solar panels convert sunlight into electricity using photovoltaic (PV) cells. This electricity can power homes and businesses or be stored for later use.
Solar energy helps reduce electricity bills, provides long-term savings, and increases property value. Additionally, many regions offer tax credits and incentives.
High-quality solar panels can last 25–30 years or more with proper maintenance, continuing to generate energy efficiently.
Yes! While solar panels generate less energy on cloudy days, battery storage solutions ensure continuous power even at night.
Contact us for a free consultation! Our experts will assess your energy needs and design a customized solar solution for your home or business.
Take the first step towards a greener tomorrow. Contact us today for a free consultation and discover how Auron can transform your energy needs!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
